Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most safety/monitoring and incidence-related claims are unsupported or partially inconsistent with the provided label text. Only the general efficacy/indication content (reduce blood Phe; BH4-responsive PKU/HPA; ≥1 month) is clearly supported by the included label excerpts.
Category Scores
Accurate Statements
JAVYGTOR reduces blood phenylalanine (Phe) levels in adult and pediatric patients 1 month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive PKU, and is indicated for this condition.
1 INDICATIONS AND USAGE: “JAVYGTOR ... is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU).”
Unsupported Statements
Sapropterin use is accompanied by side effects including headache, runny nose, sore throat, cough, diarrhea, and stomach pain.
Label provided lists common adverse reactions including headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion, but does not specifically support the inclusion/wording of “stomach pain.”
Headache, runny nose, sore throat, cough, diarrhea, and stomach pain occur in roughly one in ten patients who take sapropterin.
The provided label excerpt does not give incidence rates for these individual symptoms (e.g., “one in ten”). It only states that common adverse reactions were ≥4% of patients.
A small number of patients taking sapropterin experience low blood pressure.
No low blood pressure adverse reaction is supported by the provided adverse reactions excerpt.
A small number of patients taking sapropterin experience allergic reactions such as rash, hives, or swelling.
The provided label excerpts for adverse reactions do not mention rash/hives/swelling as such.
Doctors monitor blood pressure during the first dose of sapropterin.
The provided label text discusses monitoring blood Phe levels, not blood pressure.
Doctors watch for signs of allergy at every visit during sapropterin treatment.
No label excerpt provided states allergy monitoring at every visit.
Mild symptoms like headache or stomach upset often ease within a few days after starting sapropterin.
No label excerpt provided supports time-to-resolution statements.
If side effects persist or worsen with sapropterin, clinicians may adjust the dose or switch the patient to an alternative therapy.
The provided label excerpts describe dose adjustments based on biochemical response to therapy (blood Phe) and discontinuation after lack of biochemical response, but do not support switching based on side effects persisting/worsening.
Children and adults show similar patterns of sapropterin side effects.
No pediatric vs adult comparative adverse reaction pattern is provided in the supplied excerpts.
Younger patients sometimes have more stomach-related complaints with sapropterin.
No age-stratified adverse reaction statement supporting “more stomach-related complaints” is provided.
Dose adjustments based on weight help keep sapropterin problems manageable.
The label excerpts support dosage by mg/kg and adjustments based on biochemical response (blood Phe), not “to manage problems” from side effects.
Sapropterin can raise blood levels of methotrexate.
No drug interaction information is provided in the supplied label excerpts regarding methotrexate.
Sapropterin can raise blood levels of certain antidepressants.
No drug interaction information is provided in the supplied label excerpts regarding antidepressants.
Raising blood levels of methotrexate and certain antidepressants may intensify those drugs' own side effects.
This depends on the preceding unsupported interaction claims; no such interaction/side-effect intensification is supported by the provided excerpts.
Physicians check current medications before starting sapropterin treatment.
No label excerpt provided states a medication reconciliation requirement.
The main U.S. composition-of-matter patent for sapropterin expires in 2026.
Patent/market exclusivity information is not included in the provided prescribing information excerpts.
Expiration of the main U.S. composition-of-matter patent in 2026 could allow generic versions of sapropterin.
Not supported by prescribing information excerpts.
Generic versions of sapropterin could lower costs for patients.
Not supported by prescribing information excerpts.
Contradictions
Important Omissions
Monitoring should focus on blood Phe levels during treatment (and dietary Phe management), rather than blood pressure.
Importance:
Moderate
No support was provided for blood pressure monitoring or routine allergy monitoring at every visit; if such guidance exists in the full label, it is not reflected in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related items (blood pressure monitoring, allergy monitoring, specific incidence rates, and specific adverse reaction types) are not supported by the provided label excerpts; additionally, unsupported drug-interaction claims could mislead about concomitant drug management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific safety/monitoring, incidence, interaction, and patent/cost claims are not supported by the provided JAVYGTOR prescribing information excerpts.
Suggested Improvement
Limit claims to on-label content supported by the provided excerpts (e.g., reduce blood Phe in BH4-responsive PKU/HPA ≥1 month with Phe-restricted diet; common adverse reactions listed as ≥4% such as headache/rhinorrhea/pharyngolaryngeal pain/diarrhea/cough; monitor blood Phe levels; dose adjustments based on blood Phe response; discontinue after lack of biochemical response after adequate dosing). Remove unsupported blood pressure/allergy monitoring, quantified incidence (“one in ten”), drug interaction and patent/cost assertions unless supported by the label text provided.